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Objectives: The efficacy of different formulations of the naphthoquinone buparvaquone and two phos-
phate prodrugs in in vivo models of both visceral and cutaneous leishmaniasis is described.
Methods: Several topical formulations of buparvaquone containing acceptable excipients were tested
in vivo against Leishmania major cutaneous lesions in BALB/c mice. In vivo studies against
Leishmania donovani investigated whether the prodrugs had improved efficacy when compared with
buparvaquone.
Results: Both a hydrous gel and water-in-oil emulsion of buparvaquone significantly reduced cutaneous
parasite burden (P < 0.05, 22 days post-infection) and lesion size, compared with the untreated control
(P < 0.0001, 16 days post-infection). The prodrug 3-phosphonooxymethyl-buparvaquone was formulated
into an anhydrous gel and this also significantly reduced parasite burden and lesion size (P < 0.0001, 16
days post-infection). Histology confirmed this efficacy. In the visceral model, both prodrugs were
significantly more effective at reducing liver parasite burden than the parent drug, buparvaquone.
Buparvaquone-3-phosphate was shown to be the most effective antileishmanial (P 5 0.0003, 50 mg
buparvaquone molar equivalent/kg/day five times), reducing the liver parasite burden by 34% when
compared with the untreated control.
Conclusions: The introduction of a topical formulation, such as buparvaquone (or its prodrug), would
be a significant advance for the treatment of simple cutaneous lesions. In particular, the avoidance of
the parenteral antimonials would greatly increase patient compliance and reduce treatment costs.
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Introduction
Leishmaniasis is a worldwide disease caused by protozoan para-
sites of the genus Leishmania, which cause a range of diseases
in humans, ranging from disfiguring cutaneous lesions (CLs) to
visceral leishmaniasis (VL); the latter is fatal if left untreated.
CL is the most common form of leishmaniasis and has an
annual incidence of 1–1.5 million cases (90% of these are
found in the Old World).1 VL (also known as kala-azar) is
found in more than 80 countries in Asia and Africa (Leishmania
donovani), Southern Europe (Leishmania infantum) and South
America (Leishmania chagasi). Of the 500 000 cases annually,
more than 90% occur in Bangladesh, Brazil, Nepal, India
(especially Bihar state) and Sudan. It is estimated that India
alone accounts for up to 50% of worldwide cases.2 Treatment
for VL mainly relies on the parenteral administration of penta-
valent antimonials [e.g. 20 mg/kg/day intramuscular (im) or
intravenous (iv) sodium stibogluconate for 20 days], which are
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associated with many problems (i.e. resistance, toxicity and
cost).3 Recent advances have included the introduction of milte-
fosine and newer formulations of existing drugs, for example,
liposomal amphotericin B.4,5
In CL, the disease is normally localized to the site of infec-
tion within dermal macrophages. Typically, papules develop at
the site of infection, enlarge to a nodule and progress to ulcer-
ated lesions, which last less than a year.6 Treatment for CL
aims to accelerate healing, minimize scarring and prevent the
development of more complex manifestations. Dissemination
may occur when certain species migrate to mucosal tissue (i.e.
MCL) or multiple cutaneous sites. Systemic therapy is usually
warranted in these complex cases. However, for self-limiting
forms of CL (such as Leishmania major and Leishmania
mexicana) not at risk of more complex manifestations, topical
therapy offers a more acceptable form of treatment. Advantages
of topical therapy include reduced cost (avoid hospitalization),
lower toxicity (target drug to infected tissues) and patient com-
pliance (non-invasive administration).7 Studies in the Old
World show intralesional administration to give superior
healing rates when compared with intramuscular antimonials.8
Currently, there are only two topical formulations, commer-
cially available for the treatment of CL, both of which contain
the aminoglycoside, paromomycin, formulated as an ointment.
However, these paromomycin ointments possess problems of
varying efficacy and toxicity.9 – 12
Buparvaquone (BPQ), a hydroxynaphthoquinone shown in
Figure 1, is currently marketed as Butalexw, an im injection for
the treatment of theileriosis in cattle. It was first shown to have
antileishmanial activity against L. donovani by Croft et al.,13
where a 62% suppression of hepatic amastigote burden was
observed in L. donovani-infected BALB/c mice when BPQ
was administered subcutaneously in corn oil (100 mg/kg/day for
5 days). It has several physicochemical properties suitable for
topical delivery (low molecular weight, low melting point, etc.).
However, it also has low aqueous solubility and high lipophili-
city; therefore, the phosphate prodrug approach was investigated
in an attempt to increase aqueous solubility and absorption
(Table 1). In an earlier study, BPQ and its two phosphate pro-
drugs (shown in Figure 1), buparvaquone-3-phosphate (BPQ-3-
phos) and 3-phosphonooxymethyl-buparvaquone (3-POM-BPQ),
were shown to have potent in vitro antileishmanial activity
(nanomolar range) against species causing both visceral and
cutaneous leishmaniasis.14 Formulations of BPQ and 3-POM-
BPQ were subsequently shown to penetrate both human epider-
mal and full thickness BALB/c mouse skin in vitro.15
The aim of this study was to investigate the in vivo efficacy
and toxicity for formulations of buparvaquone and two
phosphate prodrugs in animal models for CL and VL. As
BPQ was previously shown to have potent in vivo activity in a
model for VL, studies were included using the L. donovani
BALB/c model to evaluate whether oral delivery of prodrugs
had improved efficacy when compared with BPQ.
Figure 1. Structure of buparvaquone (326.43 Da), buparvaquone-3-
phosphate (406.42 Da) and 3-POM-buparvaquone (436.45 Da); shown from
top to bottom.
Table 1. Buparvaquone prodrug physicochemical data
Properties BPQ BPQ-3-phos 3-POM-BPQ
Log D 7.02 (pH 3.0) 1.87 (pH 3.0),
1.27 (pH 5.0),
0.47 (pH 7.4)
2.96 (pH 3.0),
1.83 (pH 5.0),
1.16 (pH 7.4)
pKa 5.70 2.68; 6.74 2.28; 6.76
Melting
point (8C)
ND 121.9–124.0 ND
Aqueous
solubility
(mg/mL)
,0.03 mg/mL
(pH 3.0, pH 5.0);
0.03 mg/mL
(pH 7.4)
.3.5 (pH 3.0,
pH 5.0, pH 7.4)
.3.5 (pH 3.0,
pH 5.0, pH 7.4)
ND, not determined.
Adapted from Ma¨ntyla¨ et al.14
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Materials and methods
Materials
BPQ and Pentostam (sodium stibogluconate) were gifts from
GlaxoSmithKline, UK. The BPQ prodrugs, 3-POM-BPQ and
BPQ-3-phos, were synthesized at Kuopio University, Finland.14 All
chemicals and solvents were of the highest grade available. The for-
mulations were prepared using only FDA-approved or GRAS-listed
excipients,16 with the exception of the novel silicones, which were
supplied by Dow Corning (Coventry, UK). Isopropyl myristate
(IPM), polyethylene glycols (PEG300/400), mineral oil, glycerin,
paromomycin (as sulphate) and hydroxypropl-b-cyclodextrin
(HP-b-CD) were purchased from Sigma, Poole, UK. Klucel HF
Pharm (hydroxypropyl cellulose) was obtained from Hercules,
Hopewell, USA. Ethanol and sodium chloride were purchased from
BDH, Poole, UK. Carbopol ETD2020 was obtained from Noveon,
Cleveland, USA. Cetomacrogol 1000 (Rhodasurf ) was obtained
from Rhodia, Widnes, UK. Cetostearyl alcohol was obtained from
Paroxite, London, UK. White soft paraffin (Vaseline) was obtained
from Lever Faberge, London, UK.
Animals
BALB/c (female, 6–8 weeks) mice were obtained from Harlan
Sera-Lab, Loughborough, UK and weighed 20 g each at the time
of infection. A standard rodent diet (SDS R and M No. 1 expanded)
and de-ionized water were supplied ad libitum. Female golden
hamsters (Mesocricetus auratus), used for the routine passage of
L. donovani, were obtained from Charles River Ltd, Margate, UK.
All animals used in these studies were ‘specific pathogen free’.
Experiments were conducted under licence in accordance with UK
Home Office approval (Project Licence 70/04779).
Parasites
Promastigotes of L. major (MHOM/SA/85/JISH118) were taken
from liquid nitrogen stabilates and cultured in Schneider’s
Drosophila medium (GibcoBRL, Paisley, UK) supplemented with
10% heat-inactivated fetal calf serum (Harlan Sera-Lab, Crawley,
UK). They were maintained at 268C. L. donovani amastigotes were
isolated from the female golden hamster spleen (M. auratus).
In vivo VL leishmaniasis model
The in vivo model for VL has been described previously.17 Briefly,
BALB/c mice were infected with L. donovani HU3 inoculated intra-
venously (maximum 0.2 mL) in the lateral tail vein with 1.5107
freshly harvested amastigotes. After infection, mice were marked for
individual identification and randomly allocated into groups of five.
After 7 days, a mouse was sacrificed and parasitic burden was based
on microscopic enumerations of amastigotes against host cell nuclei
on liver impression smears.18
Dosing started on the seventh day post-infection for 5 continuous
days. As a positive control, one group received 15 mg Sbv/kg
(as sodium stibogluconate) subcutaneously for 5 days, as described
previously.19,20 In this study, an ED50 was determined to be
13.2+3.75 mg Sbv/kg. The oral formulations were made 24 h
prior to dosing each day (except the BPQ-HP-b-CD complex).
These included BPQ, the BPQ-HP-b-CD complex, 3-POM-BPQ
and BPQ-3-phosphate in 50 mM sodium acetate buffer, pH 5. The
first experiment used an oral dose of 20 mg/kg BPQ (molar equival-
ent for prodrugs) for 5 days and the second study used 50 mg/kg
BPQ (molar equivalent for prodrugs) for 5 days. Animals were
dosed once daily by oral gavage (maximum volume 0.4 mL) for
5 days, except for the Pentostam group, which was dosed subcu-
taneously in 0.2 mL.
Compound efficacy was assessed by determining microscopically
the reduction in amastigote burden within the liver. Impression
smears were taken 14 days post-infection (7 days after the start of
treatment). Slides were examined by light microscopy, using 1000
oil immersion. The number of amastigotes per 500 cell nuclei was
counted in both treated and untreated mice. Body weights were
determined pre- and post-treatment as a gross indicator of toxicity.
In vivo CL leishmaniasis model
The in vivo model for CL has been described previously.21 Briefly,
mice were infected subcutaneously (0.2 mL) with 106–107 late
stage L. major JISH118 promastigotes. Peanut agglutinin (PNA)
was used to determine the number of metacyclic promastigotes
(‘infective’ inoculum).22
The paromomycin–urea ointment was included as this is one of
the two topical formulations clinically available for CL.7,23
Cutaneous lesions were measured weekly using digital callipers
(JenconsTM) and compared with the untreated control to evaluate
therapy. Topical formulations were applied only to the lesions.
Body weights were determined for each individual mouse through-
out the study as a gross indicator of toxicity. Signs of skin irritation
were graded according to the OECD Guidelines for Testing of
Chemicals No. 404 (adopted 24 April 2002); a scale used by both
UK and US regulatory authorities. The scale is graded 1–4 for both
erythema/eschar and oedema formation, with 0 representing ‘none’
and 4 representing ‘severe’.
The first in vivo study was to investigate the toxicity/efficacy of
buparvaquone formulations. All the formulations had been tested
previously in vitro and shown to penetrate full thickness BALB/c
skin.15 The formulations included the paromomycin–urea ointment,
anhydrous gel (0.74% w/w), hydrous (0.08% w/w) and o/w emul-
sion (0.89% w/w). Mice were infected with 2.2  106 L. major
JISH118 promastigotes. These were shown to contain 15% meta-
cyclic promastigotes by PNA agglutination. Topical treatment was
started 10 days post-infection and the study was completed on the
25th day post-infection. Approximately 30–50 mg of each formu-
lation was applied daily on each mouse. Tissue samples were taken
at necropsy for real-time PCR analysis to estimate parasite burden.
The second in vivo study compared both BPQ and 3-POM-BPQ
formulations. These included a 3-POM-BPQ anhydrous gel (0.70%
w/w BPQ and 4.95% w/w 3-POM-BPQ); BPQ w/o emulsion A
(0.40% w/w); BPQ w/o emulsion B (0.46% w/w); BPQ hydrous gel
(0.21% w/w) and 3-POM-BPQ hydrous gel (0.11% w/w BPQ and
0.24% 3-POM-BPQ). Mice were infected with 2.0  106 L. major
J118 promastigotes, including 10% metacyclics as shown by PNA
agglutination. Lesions were slow to appear and topical treatment
was started 23 days post-infection. The study was completed on the
40th day post-infection. The mice had received a total of 13 doses,
which was calculated as 70–80 mg of formulation per mouse as a
daily dose. Tissue samples were taken at necropsy for real-time
PCR analysis to estimate parasite burden.
The third study again compared BPQ and 3-POM-BPQ formu-
lations. These included BPQ hydrous gel (0.05% w/w);
3-POM-BPQ anhydrous gel (2.0% w/w BPQ and 5.0% w/w
3-POM-BPQ); BPQ w/o emulsion A (0.5% w/w) and BPQ in IPM
(0.5% w/w). Mice were infected with 2.0  106 L. major J118
promastigotes (10 mice per group) and topical treatment was started
in this study 3 days after infection. The treated mice received a total
of 20 doses. At 16 and 22 days post-infection, one mouse was
Buparvaquone as an antileishmanial
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sacrificed per group and parasite burden was estimated by both real-
time PCR and the limiting dilution assay (LDA) method. Results
were expressed as number of parasites per milligram tissue. At
necropsy, one mouse per group was used for histopathology.
Real-time PCR
Parasite burden (from dermal scrapings) was determined using real-
time PCR.24 Real-time PCR analysis was carried out using an ABI
Prism 7000 Sequence Detection System (Applied Biosystems) and
the QuantiTectTM SYBRw Green PCR kit (Qiagen, UK; Cat
204143). Extraction of genomic DNA was carried out using a
DNeasyTM tissue kit (Qiagen; Cat 69 504). Three lesion samples of
10–20 mg were taken from each mouse. As a requirement for the
analysis, Picogreen (Qiagen) was used to quantify DNA in extracts.
On the basis of a 25 mL volume for the QuantiTectTM SYBRGreen
reaction, all samples tested were confirmed to be ,500 ng per reac-
tion. Tissue homogenates from naive mice were spiked with known
amounts of cultured L. major promastigotes (10-fold serial
dilutions), extracted in duplicate and assayed. A standard curve was
generated and compared with the same quantity of promastigotes in
the absence of skin.
Limiting dilution assays
LDAs were carried out to estimate the number of viable L. major
parasites within infected dermal tissue, as described previously.25,26
Briefly, serial 10-fold dilutions were prepared from homogenized
dermal scrapings and the dilutions were placed in 96-well plates
(Becton–Dickinson, Franklin Lakes, USA). Following 2 weeks
incubation at 268C, the plates were read to score the number of posi-
tive wells (containing one or more promastigotes). Estimates of
parasite frequency and hence burden were carried out using the
single-hit Poisson model equation by x2 minimization.27
Formulations
The BPQ anhydrous gels consisted of 80% w/w ST-Elastomer 10,
19% w/w cyclomethicone 5-NF and 1% w/w IPM. The
3-POM-BPQ anhydrous gels consisted of 40% v/v PEG300 and
60% v/v ethanol for gel A and 30% v/v PG and 70% v/v ethanol for
gel B. Klucel HF Pharm was used as a gelling agent (,2% w/w).
The hydrous gels consisted of 10% w/w IPM and 90% w/w car-
bopol ETD2020 mucilage (3% w/v carbopol in water). A 10% w/v
sodium hydroxide solution was used to neutralize the final
formulation.
The BPQ w/o emulsion (A) consisted of 19% w/w mineral oil,
6% w/w IPM, 2% w/w emulsifier 10, 2% w/w sodium chloride and
71% w/w water. The w/o emulsion (B) consisted of 10% w/w
cyclomethicone 5NF, 10% w/w IPM, 5% w/w dimethiconol 20, 2%
w/w silky wax 10, 2% w/w emulsifier 10, 1% w/w sodium chloride,
3% w/w glycerin and 67% w/w water. The BPQ o/w emulsion
consisted of 75% w/w carbopol ETD2020 mucilage (3% w/v
carbopol in water), 3.5% w/w PG, 0.5% w/w cetomacrogol 1000,
12% w/w IPM, 4.5% w/w ST wax 30 and 4.5% w/w cetostearyl
alcohol. A 10% w/v sodium hydroxide solution was used to neutral-
ize the final formulation. All formulations were stored in glass
borosilicate vials at 2–88C and protected from light.
The BPQ suspension for oral dosing was prepared daily as 1 mg/mL
in sodium acetate buffer (50 mM, pH 5) and shaken vigorously just
prior to administration using a maximum volume of 0.4 mL (20 mg/
kg and then 50 mg/kg). Both BPQ-3-phosphate and 3-POM-BPQ
were dosed at the same molar equivalent to BPQ for each study.
Suspensions were prepared daily in sodium acetate buffer (50 mM,
pH 5). For the BPQ-HP-b-CD complex, a 16% HP-b-CD solution
in sodium acetate (50 mM, pH 5) was prepared. The required
amount of BPQ was added and the mixture constantly stirred for
72 h before filtering with a Durapor 0.45 mm filter.
The paromomycin–urea ointment was prepared as 15% paromo-
mycin (as sulphate) and 10% urea formulated in a white soft paraffin
base.28
Statistical methods
Statistical analysis of the different topical formulations on both
lesion size and parasite burden was performed using the Kruskal–
Wallis [non-parametric analysis of variance (ANOVA)] and
Dunnett’s multiple comparison tests (GraphPad InStat, version 3.05
for Windows 95/NT, GraphPad software, San Diego, CA, USA,
www.graphpad.com). Statistical analysis of the VL treatment groups
on parasite burden used a one-way ANOVA. The Kolmogorov–
Smirnov test was used to ensure normal distribution of data. Results
were considered significant when P, 0.05.
Histopathology
Whole skin lesions (one per treatment group) were fixed using for-
malin and sections were then stained using haematoxylin and eosin
(H&E). Slides were examined by light microscopy, using 1000 oil
immersion. Photomicrographs were taken using a Zeiss AxioplanTM
optical microscope and digital images captured with Optronics
MagnafireTM SP Live.
Results
L. major-infected BALB/c (model for CL)
Comparison of treatment for early and late infection in CL. For
the initial study, topical treatment was started 10 days post-
infection and mice received a total of 14 daily applications for
BPQ formulations. On the first day of treatment, lesions
measured 5 mm in diameter. Lesions treated with BPQ formu-
lations were smaller and did not ulcerate in comparison with the
untreated control. None of the lesions healed completely and
therefore a mean lesion diameter was recorded (Figure 2).
Figure 2. Mean lesion diameter of BALB/c mice (infected with L. major
JISH118) treated with buparvaquone formulations versus control
(n ¼ 6+SEM).
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BPQ-treated lesions had reduced mean lesion diameters. Two of
the BPQ formulations, the o/w emulsion and hydrous gel,
caused a significant decrease in the parasite burden, compared
with the untreated control (P , 0.0001) (Figure 3).
In the second study, there was a delay in lesion appearance
and treatment was only initiated 23 days post-infection. Mice
received a total of 13 daily applications for BPQ and
3-POM-BPQ formulations. On the first day of treatment, lesions
measured were 3 mm in diameter. By the end of treatment, no
treatment group showed a significantly different mean lesion
size when compared with the untreated control (Figure 4,
P . 0.05). However, two mice from the 3-POM-BPQ anhydrous
gel group and one mouse from the 3-POM-BPQ hydrous gel
group had re-epithelialized skin. All other mice had ulcerated
lesions. Using a one-way ANOVA with Dunnett’s multiple com-
parison test (GraphPad InStatTM), no formulation was found to
be significantly different in parasite burden (real-time PCR),
compared with the untreated control (P . 0.05).
In the third study, topical treatment was started 3 days post-
infection to maximize the opportunity of demonstrating differ-
ences between the formulations. Mice received a total of 20
daily applications for BPQ and 3-POM-BPQ formulations.
Lesions appeared 10 days post-infection. Thirteen days after
the start of treatment, all treated groups had significantly smaller
lesions (P , 0.0001) than the untreated control (Figure 5). At 25
days post-infection, the untreated control mice had developed
ulcerated lesions. Lesions had slowly begun to develop in a few
of the treated groups, but were much smaller and none had
ulcerated. Both the BPQ hydrous formulation and the
3-POM-BPQ anhydrous formulation significantly decreased
parasite burden (P, 0.001) (Figure 6). Histopathology sections
stained with H&E are shown in Figure 7. The untreated control
section clearly shows a large infiltration of infected host cells
throughout the dermal layer. Sections from treated mice did not
show infected host cells or inflammatory response cells. This
indicates that the topical treatment used in this study reduced
parasite burden in the locally infected tissues. Although in this
study, only one mouse was used per group for the histopathology
samples.
Comparing the three studies, treatment of early stage infec-
tion showed the greatest differences between formulations. In
particular, commencement of treatment prior to the appearance
of any lesions produced a significant decrease in both the mean
lesion diameter and parasite burden when compared with the
untreated control.
Differences in topical formulations. In the initial study, all
formulations were well tolerated. The percentage change in
Figure 3. Skin parasite burden per milligram tissue sample (n ¼ 3+SEM)
for BALB/c mice (infected with L. major JISH118) treated with
buparvaquone formulations as determined by real-time PCR.
Figure 5. Mean lesion diameter versus time of BALB/c mice (infected
with L. major JISH118) treated with BPQ and 3-POM-BPQ formulations
(P values from one-way ANOVA using Dunnett’s multiple comparison
post-test), n ¼ 10+SEM.
Figure 4. Mean lesion diameter of BALB/c mice (infected with L. major
JISH118) treated with BPQ versus 3-POM-BPQ formulations (n ¼ 6+SEM).
Figure 6. Parasite burden per milligram tissue sample for BALB/c mice
(infected with L. major JISH118) treated (n ¼ 3+SEM) 22 days
post-infection, as determined by real-time PCR.
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the mean body weight of mice (n ¼ 5) includes untreated
20.4%, paromomycin–urea 20.8%, anhydrous gel þ1.6%,
hydrous gel þ0.8% and o/w emulsion 20.1%. Lesions treated
with BPQ formulations were smaller (minimum 5.3 mm) and
did not ulcerate in comparison with the untreated control
(minimum 7.1 mm). Both the BPQ o/w emulsion and BPQ
hydrous gel caused a significant decrease in parasite burden
when compared with the untreated control (P , 0.0001)
(Figure 3). The group treated with the BPQ hydrous gel had less
than half the parasite burden of the untreated control.
In the second study, all formulations were well tolerated,
except for some slight erythema caused by the 3-POM-BPQ
anhydrous gel. This formulation contained 30% v/v PG, which
is known to cause irritation. The percentage change in the mean
body weight of mice (n ¼ 5) includes untreated þ8.7%,
3-POM-BPQ anhydrous gel þ3.7%, hydrous BPQ w/o emulsion
A þ6.0%, BPQ w/o emulsion B þ7.5%, BPQ hydrous gel
þ6.3% and 3-POM-BPQ hydrous gel 20.2%. Two mice from
the 3-POM-BPQ anhydrous gel group and one mouse from the
3-POM-BPQ hydrous gel group had re-epithelialized skin.
However, there was no significant difference in either lesion size
or parasite burden for any of the treatment groups in comparison
with the untreated control. However, treatment with the BPQ
hydrous gel did decrease the parasite burden.
In the third study, skin reactions were seen in several mice
treated with anhydrous 3-POM-BPQ, although the skin condition
improved by the study end. The erythema and oedema were
graded as 3 and 2, respectively, by OECD guidelines. This was
Figure 7. Histopathology sections for BALB/c mice (infected with L. major JISH118) treated with: (a) untreated control; (b) BPQ hydrous gel; (c)
3-POM-BPQ anhydrous gel; (d) BPQ w/o emulsion and (e) BPQ in IPM (H&E stain, magnification 100).
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the only group that showed a decrease in the mean body weight
and this is probably due to the relatively high concentrations of
solvents used. Both ethanol and PG are known to cause irri-
tation, and systemic uptake could also have occurred. One
mouse in the BPQ emulsion group lost hair around the treated
area and erythema/oedema occurred and the treatment was
stopped after six doses. The skin condition in this mouse was
graded as 2 for erythema by OECD guidelines. The percentage
change in the mean body weight (n ¼ 10) was untreated
þ4.0%, BPQ hydrous gel þ2.4%, 3-POM-BPQ anhydrous gel
21.1%, BPQ w/o emulsion A þ5.5% and BPQ in IPM þ5.1%.
Estimates of parasite burden at 22 days post-infection showed
that both the BPQ hydrous gel and 3-POM-BPQ anhydrous gel
caused a lower parasite burden in the mice than the untreated
control (P , 0.001) (Figure 6). Similarly, the BPQ w/o emulsion
had a significantly lower burden (P, 0.05). Estimates of para-
site burden using the final titre method showed that all treatment
groups had a reduced parasite burden by 26 days post-infection.
In particular, the BPQ w/o emulsion showed a reduced parasite
burden when compared with the untreated control at the three
different time points when samples were taken (16, 22 and 26
days post-infection). For example, at 22 days post-infection, the
group treated with the BPQ hydrous gel had less than one-fifth
the parasite burden of the untreated control (Figure 6).
The formulations that showed the greatest efficacy (reduced
lesion size and parasite burden) were the BPQ w/o emulsion,
BPQ hydrous gel and the 3-POM-BPQ anhydrous gel. Both
BPQ formulations were well tolerated. However, the
3-POM-BPQ anhydrous gel caused some local skin reactions.
L. donovani-infected BALB/c (model for VL)
The first VL experiment using L. donovani-infected BALB/c
mice was carried out to investigate whether the BPQ prodrugs
had improved activity when compared with BPQ (20 mg/kg for
5 days). Both the Pentostam control group and the prodrug
groups had approximately two-thirds the parasite burden (shown
by real-time PCR) of the untreated control (Figure 8). Using a
Kruskal–Wallis (non-parametric ANOVA) test, the difference
was significant (P , 0.0001). At the same molar equivalent, the
BPQ-3-phosphate prodrug appeared to be the most effective.
Neither the BPQ suspension nor BPQ-CD formulation caused a
significant decrease in parasite burden. No toxic effects were
noted in any of the groups, although the BPQ-CD group was the
only one to have a reduced mean body weight post-treatment
(1.6% decrease).
The second experiment investigated higher doses using
50 mg/kg for 5 days. The effect of increasing BPQ solubility was
also examined by using solvents, which had animal toxicity data
to support oral dosing.16 Liver smears again indicated that both
BPQ prodrugs significantly reduced parasite burden (Figure 9).
Using a Kruskal–Wallis test (non-parametric ANOVA), the
difference was significant (P ¼ 0.0003). The BPQ-3-phosphate
prodrug was again shown to be the most effective drug at redu-
cing parasite numbers (Figure 9). The parasite burden in the
BPQ-3-phosphate group was 34% of the parasite burden in the
untreated control. Both BPQ treatment groups, IPM and PEG400,
reduced the parasite burden to a greater extent than the BPQ sus-
pension (50 mM sodium acetate buffer pH 5). A higher BPQ
dose was used than in the last study and the BPQ suspension did
reduce parasite burden but was least effective of all the formu-
lations. However, it should be noted that the parasite burden for
the untreated control was greater in the first L. donovani study
than in the second study. The liver parasite burden for the
untreated control in the first in vivo was approximately four times
higher. Toxic effects were seen in the 3-POM-BPQ group, which
included a reduction in the mean body weight, poor hair con-
dition and a hunched appearance.
Discussion
BPQ was chosen for further studies as a topical formulation
for CL and oral formulation for VL on the basis of its potent
in vitro antileishmanial activity.13,15 It also has several physico-
chemical properties suitable for skin penetration (low molecular
weight, low melting point, etc.). However, the low aqueous solu-
bility of BPQ resulted in several phosphate prodrugs being
investigated to improve aqueous solubility and enhance skin
absorption.
The experiments on BALB/c mice infected with L. major
indicate that topical formulations of both BPQ and its prodrug,
3-POM-BPQ, delay lesion progression and reduce parasite
Figure 9. Liver parasite burden for BALB/c mice infected with L. donovani
HU3 (n ¼ 5+SEM) dosed at 50 mg/kg BPQ (molar equivalent for prodrugs)
for 5 days, as determined by real-time PCR.
Figure 8. Liver parasite burden for BALB/c mice infected with L. donovani
HU3 (n ¼ 5+SEM) dosed at 20 mg/kg BPQ (molar equivalent for prodrugs)
for 5 days, as determined by real-time PCR.
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burden (up to seven times decrease). Several factors can cause
differences in efficacy and are important in the evaluation of
topicals. The timing for start of treatment can greatly influence
the disease outcome. Topical treatment was started 3, 10 and 23
days post-infection in the three studies. Treatment started just 3
days post-infection had a more significant effect on lesion
progression when compared with treatment started 10 or 23
days post-infection (P, 0.001). Initial screening of potential
antileishmanials should be tested in early stage infections to
maximize the opportunity for demonstrating differences in for-
mulations. In this particular model, parasites have been shown
to disseminate from the infection site within 24 h post-
infection.29 The delay in treatment could have greatly affected
the treatment outcome. In particular, an altered cytokine profile
within the initial stages of infection is thought to influence
disease progression. As the BALB/c L. major model is non-cure,
the start of treatment early after infection is likely to provide the
most sensitive model for drug screening. In future studies, a self-
cure mouse model, such as C57Bl, could be investigated.
Topical efficacy is likely to be more easily demonstrated in the
early stages of infection than on well-established lesions. It has
been well established in immunological studies that the course
of infection can be manipulated with certain treatments (IL12,
sublethal irradiation, anti-IL4 mAb, anti-CD4 mAb), but only in
the early days after infection.21,30,31 Depending on a drug’s
mode of action, this may also be the case for successful topical
treatment. Evaluation of drug treatment for CL on established
infections might miss potentially valuable formulations. In the
clinical situation, patients usually only seek medical intervention
on well-established lesions. However, simple human CL
(L. major and L. mexicana) is a self-curing disease and the para-
site burden is mainly confined to the site of infection. In com-
parison, the BALB/c mouse develops chronic progressive
lesions and parasites are known to disseminate from the infec-
tion site within hours. In the second study, there was a pro-
nounced delay in lesion appearance; the reason for this is not
apparent. The infecting parasites were re-confirmed as being
L. major and the calculations for infective dose inoculum were
found to be correct. The effect of treatment should be investi-
gated on both initial and late stage infections, as both the skin
condition and parasite distribution can alter disease outcome.
Topical efficacy was determined by monitoring both lesion
progression and parasite burden. The paromomycin ointment,
which was initially included as a positive control, was shown to
improve the clinical appearance of lesions; however, no signifi-
cant decrease in parasite burden could be demonstrated.
Therefore, evaluation of potential topical treatments for CL
should include both parasite burden and lesion size for efficacy.
Previous studies have usually not included both these criteria and
their results have been difficult to interpret. For monitoring lesion
progression, the mean lesion size was measured over the course
of the study. Parasite burden was quantified by both LDAs and
real-time PCR. Although both real-time PCR and the final titre
method indicated significant decreases in parasite burden, the
magnitude of decrease caused by the formulations varied between
each of these methods. The real-time PCR method quantifies total
kDNA, which can include both live and dead parasites. The
LDAs are based on the ability of viable parasites to grow and
replicate in culture. It is essential that suitable markers and less
invasive markers are developed to enable measurement of drug
activity (e.g. Katex). L. major parasite dissemination in BALB/c
mice is known to occur within 10–24 h post-infection, so even a
temporary reduction in parasite burden is likely to indicate suc-
cessful local killing of parasites.29 Further studies would be inter-
esting in a self-cure mouse strain (e.g. CBA) to determine
whether treatment can prevent lesion appearance.
The differences in efficacy between the parent compound BPQ
and the prodrug 3-POM-BPQ may be due to differences in formu-
lation type, in addition to their intrinsic antileishmanial activity.
Previous in vitro studies13,15 showed a different rank order of pen-
etration for the formulations between the mouse and human skin.
Therefore, formulations optimized both in vitro and in vivo on
animal skin will probably behave quite differently when applied
on human skin. Excipients can greatly influence skin penetration,
so future studies should investigate optimizing the lead formu-
lations and, in particular, determining stability for each one. It
would also be worth testing further prodrugs of buparvaquone
and optimizing each formulation for the particular skin type.
In general, the topical formulations were well tolerated,
although some irritancy was noted with the 3-POM-BPQ anhy-
drous gel and BPQ w/o emulsion. The OECD test guideline 404
provides a grading scale for in vivo irritation, used by both US
and UK regulatory authorities.32 Using these criteria, the
3-POM-BPQ anhydrous gel caused erythema and oedema in
several mice between grade 1 and 2. These might be due to the
prodrug itself or the released BPQ. Improvements in bioavail-
ability can increase toxicity as well as efficacy. One excipient in
this formulation is propylene glycol, which was previously
shown to cause no signs of irritancy after 24 h contact in hairless
mice at 100%.33 PG is GRAS listed in the FDA inactive ingredi-
ents and is classed as a minimal irritant. The main excipient,
ethanol, is a known mild irritant (especially .50%) and may
cause contact dermatitis. Further development of formulations
should aim to reduce irritancy. The bad skin reaction (grade 3
erythema/oedema), which occurred due to the BPQ w/o emul-
sion, was only seen in one mouse. Owing to its severity, dosing
was stopped in this particular mouse and the skin recovered over
the following days.
In the L. donovani studies, both BPQ prodrugs caused a sig-
nificant decrease in the liver parasite burden. Both studies indi-
cated that the prodrug, buparvaquone-3-phosphate, was the most
effective at reducing parasite burden. The difference between
prodrugs could be due to several factors, for example, stability,
rate of parent compound release or pharmacokinetics. In the
second study, BPQ was administered orally as a solution in the
solvents IPM and PEG400. These were chosen because of good
BPQ solubility and oral excipient tolerability. The availability of
the drug in solution as opposed to suspension is likely to
improve dissolution within the gastrointestinal tract and ulti-
mately enhance bioavailability. These results confirm improved
efficacy with the BPQ prodrugs and this is most likely due to
enhanced absorption and greater bioavailability. The increased
solubility in the solvents also led to a much greater reduction in
parasite burden when compared with the suspension formulation
of BPQ at the equivalent dose. This highlights the importance of
solubility in absorption and also choosing the optimal excipients
as a drug vehicle for in vivo evaluations. The improved efficacy
of the prodrugs also confirms that optimizing physicochemical
properties can greatly enhance bioavailability and efficacy.
These results confirm that buparvaquone is a potent antileishma-
nial and warrants further investigation of both BPQ and its phos-
phate prodrugs for the treatment of VL.
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Apart from the development of paromomycin topicals (in the
1980s), there have been few advances in the treatment of CL.
Excipients should also be chosen that are suitable not only for
the drug but also for the end user. The use of methylbenzetho-
nium chloride in one of the paromomycin ointments highlights
this fact, as it is known to cause skin irritancy. The introduction
of a topical formulation, such as buparvaquone, would be a sig-
nificant advance for the treatment of simple CL. In particular,
the avoidance of the parenteral antimonials would greatly
increase patient compliance and reduce treatment costs.
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